RETRACTED ARTICLE: Discovery of novel benzohydroxamate-based histone deacetylase 6 (HDAC6) inhibitors with the ability to potentiate anti-PD-L1 immunotherapy in melanoma
Journal of Enzyme Inhibition and Medicinal Chemistry · 31.12.2023 · 38 (1)
DOI: 10.1080/14756366.2023.2201408 ↗Kurz gefasst
Zurückgezogene Publikation in der Zeitschrift Journal of Enzyme Inhibition and Medicinal Chemistry, online erschienen am 25.04.2023. Verfasst von Xiaopeng Peng und 11 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy, Gannan Medical University, Ganzhou, China. Hauptthemen laut MEDLINE: CD8-Positive T-Lymphocytes, Histone Deacetylase Inhibitors, Melanoma. Die Arbeit wurde bisher 22-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Science and Technology Projects of Ganzhou, Start-Up Foundation of Gannan Medical University.
Abstract (Originalsprache)
In this study, a novel series of histone deacetylases 6 (HDAC6) inhibitors containing polycyclic aromatic rings were discovered and evaluated for their pharmacological activities. The most potent compound 10c exhibited high HDAC6 inhibitory activity (IC50 = 261 nM) and excellent HDAC6 selectivity (SI = 109 for HDAC6 over HDAC3). 10c also showed decent antiproliferative activity in vitro with IC50 of 7.37-21.84 μM against four cancer cell lines, comparable to that of tubastatin A (average IC50 = 6.10 μM). Further mechanism studies revealed that 10c efficiently induced apoptosis and S-phase arrest in B16-F10 cells. In addition, 10c markedly increased the expression of acetylated-α-tubulin both in vitro and in vivo, without affecting the levels of acetylated-H3 (marker of HDAC1 inhibition). Furthermore, 10c (80 mg/kg) exhibited moderate antitumor efficacy in a melanoma tumour model with a tumour growth inhibition (TGI) of 32.9%, comparable to that (TGI = 31.3%) of tubastatin A. Importantly, the combination of 10c with NP19 (a small molecule PD-L1 inhibitor discovered by us before) decreased tumour burden substantially (TGI% = 60.1%) as compared to monotherapy groups. Moreover, the combination of 10c with NP19 enhanced the anti-tumour immune response, mediated by a decrease of PD-L1 expression levels and increased infiltration of anti-tumour CD8+ T cells in tumour tissues. Collectively, 10c represents a novel HDAC6 inhibitor deserving further investigation as a potential anti-cancer agent.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Pharmacy, Gannan Medical University, Ganzhou, China.
- School of Pharmaceutical Sciences, Guangdong Provincial Key Laboratory of New Drug Screening, Southern Medical University, Guangzhou, China.
- Instrumental Analysis Center, Shanghai Jiao Tong University, Shanghai, China.
- School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, China.
Förderung
- National Natural Science Foundation of China
- Science and Technology Projects of Ganzhou
- Start-Up Foundation of Gannan Medical University
- Thousand Youth Talents Program
- Organization Department of the CPC Central Committee and International Science and Technology Cooperation Projects of Guangdong Province
Zitieren
APA
Peng, X., Yu, Z., Surineni, G., Deng, B., Zhang, M., Li, C., Sun, Z., Pan, W., Liu, Y., Liu, S., Yu, B., & Chen, J. (2023). RETRACTED ARTICLE: Discovery of novel benzohydroxamate-based histone deacetylase 6 (HDAC6) inhibitors with the ability to potentiate anti-PD-L1 immunotherapy in melanoma. Journal of Enzyme Inhibition and Medicinal Chemistry, 38(1). https://doi.org/10.1080/14756366.2023.2201408
Vancouver
Peng X, Yu Z, Surineni G, Deng B, Zhang M, Li C, et al. RETRACTED ARTICLE: Discovery of novel benzohydroxamate-based histone deacetylase 6 (HDAC6) inhibitors with the ability to potentiate anti-PD-L1 immunotherapy in melanoma. Journal of Enzyme Inhibition and Medicinal Chemistry. 2023;38(1). doi:10.1080/14756366.2023.2201408
BibTeX
@article{Peng2023,
author = {Peng, Xiaopeng and Yu, Ziwen and Surineni, Goverdhan and Deng, Bulian and Zhang, Meizhu and Li, Chuan and Sun, Zhiqiang and Pan, Wanyi and Liu, Yao and Liu, Shenglan and Yu, Bin and Chen, Jianjun},
title = {RETRACTED ARTICLE: Discovery of novel benzohydroxamate-based histone deacetylase 6 (HDAC6) inhibitors with the ability to potentiate anti-PD-L1 immunotherapy in melanoma},
journal = {Journal of Enzyme Inhibition and Medicinal Chemistry},
year = {2023},
volume = {38},
number = {1},
doi = {10.1080/14756366.2023.2201408}
}
EUVIMED